Latest Quark Pharmaceuticals Stories
LONDON, September 25, 2012 /PRNewswire/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2012. Ali Mortazavi, Director of Corporate Strategy, said: "These results, including the writedown of our Intradigm investment, mark the end of a very difficult period for Silence Therapeutics. However, post this period, the Company has been...
LONDON, June 6, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference [http://silence-therapeutics.com/platform-technologies/rna-interference ] (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At...
LONDON, May 17, 2012 /PRNewswire/ -- - Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics...
LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics Plc [http://silence-therapeutics.com ] (AIM: SLN), a leading international RNAi therapeutics company [http://silence-therapeutics.com/pipeline/clinical-programs/#!/about-us ], today announces its unaudited preliminary results for the year ended 31 December 2011. HIGHLIGHTS - Impressive interim data from Phase I trials of Atu027 (lead programme in metastatic cancer) presented at...
LONDON, March 9, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, responds to comments that the Tuschl I (EP 1309726) patent has been upheld in European Opposition Proceedings without any modification. Concluding on 1 March 2012, the European Patent Office held oral...
LONDON, February 10, 2012 /PRNewswire/ -- -- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christely resigns as a Director of the Company -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi)...
LONDON, January 6, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://www.silence-therapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune. The first collaboration...
FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION). QPI-1007 exhibited no dose...
LONDON, December 20, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company") a leading global RNA [http://silence-therapeutics.com/content/scienceofrnai/overview.htm ]interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in...
LONDON, September 21, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Tony Sedgwick PhD, FRCPath as Chief Business Officer with immediate effect. Dr Sedgwick will be based in Silence's London office and lead the growing Business Development team within Silence. Tony Sedgwick is an experienced biotechnology and...
